---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-24-002861"
form_type: "8-K"
ticker: "APTOF"
cik: "0000882361"
company_name: "Aptose Biosciences Inc."
filed_at: "2024-05-14T23:59:59+00:00"
generated_at: "2026-06-02T01:39:19.370376+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Aptose posts Q1 net loss of $9.6M; advances TUS+VEN+HMA triplet to clinical site activation

## Summary
- Net loss of $9.6M ($0.73/share) vs $13.7M ($2.22) a year ago; cash $9.3M expected to fund through August 2024.
- Tuspetinib triplet (TUS+VEN+HMA) protocol for ND AML submitted to FDA; clinical sites being activated; initial data expected Q4 2024.
- Stockholders' equity positive $137k as of March 31, but Nasdaq equity deficiency notice remains; compliance plan due May 17, 2024.
- EHA 2024 poster accepted for TUS monotherapy and TUS+VEN doublet data in R/R AML; preclinical data showing TUS activity against VEN-resistant AML.
- Nasdaq compliance regained regarding Hanmi warrant issue; second deficiency notice for equity minimum still open.

## SEC filing metadata
- accession: 0001171843-24-002861
- form_type: 8-K
- ticker: APTOF
- cik: 0000882361
- company_name: Aptose Biosciences Inc.
- filed_at: 2024-05-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/882361/000117184324002861/0001171843-24-002861-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/882361/000117184324002861/f8k_051424.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-24-002861
- JSON: https://secwatch.observer/filing/0001171843-24-002861.json
- Plain text: https://secwatch.observer/filing/0001171843-24-002861.txt

## Key facts
- Earnings Releases
  Aptose Biosciences Inc. reported financial results for first quarter ended March 31, 2024.
  - Period: first quarter ended March 31, 2024
  - Result: reported results
  source text: Aptose Biosciences Inc. ("Aptose" or the "Company") (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral targeted agents to treat hematologic malignancies, today announced financial results for the first quarter ended March 31, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/882361/000117184324002861/0001171843-24-002861-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.